S. Usen et al., EPIDEMIOLOGY OF INVASIVE PNEUMOCOCCAL DISEASE IN THE WESTERN REGION, THE GAMBIA, The Pediatric infectious disease journal, 17(1), 1998, pp. 23-28
Background. Streptococcus pneumoniae is a major cause of morbidity and
mortality in young children in the developing world, The recent devel
opment of pneumococcal polysaccharide/protein conjugate vaccines may m
ake possible prevention of this infection, However, little is known ab
out the epidemiology of invasive pneumococcal disease in children in t
he developing world, Objectives, To determine the incidence and epidem
iologic features of invasive pneumococcal disease in children resident
in a semiurban area of The Gambia. Method, The study was part of a la
rge trial of an Haemophilus influenzae type b vaccine that recruited 4
2 848 children at the age of 2 months during the period March, 1993, t
o October, 1995, Follow-up of study children continued until December
31, 1995; therefore the first children to enter the trial were followe
d for 2.5 years and the last for just a few months. During the period
of surveillance, 2256 children were investigated for possible invasive
pneumococcal disease when they presented to a hospital or health cent
er, Results, We detected 110 cases of pneumococcal disease. Pneumonia
was the most common form of invasive pneumococcal disease observed (75
.5% of patients), The incidence of pneumococcal disease was 224 [95% c
onfidence interval (CI) 171, 277] per 100 000 child years among childr
en ages 2 to 11 months, 139 (95% CI 93, 184) per 100 000 among childre
n ages 12 to 23 months and 82 (95% CI 21, 143) per 100,000 among child
ren ages 24 to 35 months. Pneumococci of serogroups 14, 6, 5, 23, 19,
46 and 2 were isolated most frequently, Susceptibility to pneumococcal
disease was not increased significantly among Haemophilus influenzae
type b-vaccinated children, Conclusions, The pneumococcus is a major c
ause of bacterial infection in The Gambia, A proposed nine-valent pneu
mococcal conjugate vaccine for developing countries containing conjuga
tes of serogroups 1, 4, 5, 6, 9, 14, 18, 19 and 23 would cover 74%% of
cases of invasive pneumococcal disease in children resident in the We
stern Region of The Gambia.